<DOC>
	<DOCNO>NCT00162851</DOCNO>
	<brief_summary>This Phase II trial study safety tolerability subcutaneous alemtuzumab administer without dose escalation patient advance B-cell chronic lymphocytic leukemia ( B-CLL ) .</brief_summary>
	<brief_title>Study Evaluate Safety Subcutaneous Alemtuzumab Patients With B-Cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>BCLL fail fludarabine Performance status grade 3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2005</verification_date>
</DOC>